生命科学资讯

Sanofi's tolebrutinib woes pile up with FDA delay, trial miss

Lumexa Imaging tallies $462.5M in IPO, doubling original target

Philips claims AI coronary imaging developer SpectraWAVE

Kyverna gains clear view to first CAR-T approval for autoimmune disease after 'truly remarkable' SPS readout

Areteia Therapeutics to wind down after terminating Phase 3 asthma studies

Immunome's rare tumor drug passes Phase 3 test, could challenge Merck KGaA

Thermo Fisher Expands Gibco Bacto CD Portfolio with New E. coli Media - Contract Pharma

Biggest gainers and losers for Dec. 8-12, 2025

Twists, tangles, and transcription: Does epigenetics play a role in Alzheimer's? - Illumina

Agilent Technologies (NYSE:A) Upgraded at Barclays - MarketBeat

Agilent Technologies (A) Receives Analyst Rating Upgrade by Barc - GuruFocus

Sanofi returns to Dren Bio for another B cell depletion therapy at $100M upfront

Wells Fargo Adjusts PT on Thermo Fisher Scientific to $675 From $635, Maintains Overweight Rating - marketscreener.com

Kyverna to seek first clearance of a CAR-T therapy for autoimmune disease

After years of debate, the Biosecure Act could be headed for Trump’s desk

Chinese researchers divulge new WRN inhibitors

Minova Pharmaceutical and Precision Brain Science describe new salts of deuterated dextromethorphan

New KIF18A inhibitors disclosed in Inventisbio patent

Apollo AP45 discovers new PERK inhibitors

Lonza CHI: Organic capsules for next-gen plant-based nutraceuticals - nutritioninsight.com